Boston Scientific Corporation $BSX Shares Sold by Quadrant Capital Group LLC

Quadrant Capital Group LLC lowered its holdings in Boston Scientific Corporation (NYSE:BSX) by 70.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,732 shares of the medical equipment provider’s stock after selling 47,951 shares during the quarter. Quadrant Capital Group LLC’s holdings in Boston Scientific were worth $855,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BlackRock Inc. bought a new stake in Boston Scientific in the 2nd quarter worth about $5,534,781,000. Primecap Management Co. CA bought a new position in Boston Scientific during the 2nd quarter valued at about $2,156,233,000. Janus Henderson Group PLC lifted its stake in Boston Scientific by 31.0% during the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after acquiring an additional 3,907,981 shares during the period. Amundi boosted its holdings in shares of Boston Scientific by 13.8% during the 1st quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after acquiring an additional 1,707,754 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Boston Scientific by 25.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after acquiring an additional 2,856,040 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Needham & Company LLC reduced their price target on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, July 8th. Canaccord Genuity Group dropped their target price on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Wells Fargo & Company cut their target price on shares of Boston Scientific from $50.00 to $48.00 and set an “equal weight” rating for the company in a research report on Wednesday, September 23rd. Jefferies Financial Group cut their target price on shares of Boston Scientific from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Piper Sandler decreased their target price on shares of Boston Scientific from $65.00 to $60.00 in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $68.23.

Boston Scientific Trading Down 0.7%

Boston Scientific stock opened at $45.67 on Friday. The business has a 50-day simple moving average of $45.46 and a two-hundred day simple moving average of $49.16. The company has a market cap of $66.19 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.10 and a beta of 0.58. Boston Scientific Corporation has a 52-week low of $41.38 and a 52-week high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the firm earned $0.75 EPS. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific Corporation will post 3.24 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Habiger acquired 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.